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Abstract: 
Stroke mortality and morbidity is expected to rise. Despite considerable recent advances within acute ischemic 
stroke treatment, scope remains for development of widely applicable neuroprotective agents.  
 
Glucagon like peptide-1 receptor agonists (GLP-1RAs), originally licensed for the management of Type 2 
Diabetes Mellitus, have demonstrated pre-clinical neuroprotective efficacy in a range of neurodegenerative 
conditions.  
 
This systematic scoping review reports the pre-clinical basis of GLP-1RAs as neuroprotective agents in acute 
ischemic stroke and their translation into clinical trials.  
 
We included 35 pre-clinical studies, 11 retrospective database studies, 7 cardiovascular outcome trials and 4 
prospective clinical studies. 
 
Pre-clinical neuroprotection was demonstrated in normoglycemic models when administration was delayed by up 
to 24-hours following stroke induction. Outcomes included reduced infarct volume, apoptosis, oxidative stress 
and inflammation alongside increased neurogenesis, angiogenesis and cerebral blood flow. Improved neurological 
function and a trend towards increased survival were also reported.  
 
Cardiovascular outcomes trials reported a significant reduction in stroke incidence with semaglutide and 
dulaglutide. Retrospective database studies show a trend towards neuroprotection. Prospective interventional 
clinical trials are on-going, but initial indicators of safety and tolerability are favourable.  
 
Ultimately, we propose that repurposing GLP-1RAs is potentially advantageous but appropriately designed trials 
are needed to determine clinical efficacy and cost-effectiveness.  
 
Five key words: Acute Stroke, Neuroprotection, Reperfusion, Clinical Trials, Animal Models  
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Introduction: 
 
Stroke accounts for 6.5 million deaths per year globally and by 2030 will result in the annual loss of over 200 
million disability adjusted life years.1,2 With an increasing number of strokes occurring in younger patients, 
alongside an increased number of stroke survivors, the cost of post-stroke care rising. There is, therefore, 
significant scope to improve upon the current position. 
 
Considerable advances have been made in acute ischemic stroke (AIS) treatment, notably reperfusion therapies, 
but these are limited to 10-20% of total stroke patients following careful clinical and radiological selection.3 Even 
when intravenous thrombolysis and/or endovascular thrombectomy are administered, reduction in disability is 
highly time dependent.4,5 Scope remains for further improvement, especially for patients who are unsuitable for 
reperfusion therapies or those within remote environments.  
 
Using simpler clinical selection processes, neuroprotective therapies could bring benefits to a wider patient 
group. Neuroprotectants could also enhance the benefits of reperfusion therapies by preservation of the ischemic 
penumbra and reduction in ischemic reperfusion injury. Despite many demonstrating pre-clinical potential, a 
suitable agent has not yet been identified by translational studies.6 There remains a multitude of factors affecting 
the translation from bench-to-bedside. Namely, animal models are not perfect in their representation of the 
heterogeneity of clinical stroke.7 Stroke in humans occurs in the context of ageing, co-morbidity (hypertension, 
diabetes mellitus, atrial fibrillation, pre-existing cerebrovascular disease) and concomitant medication use.8 
Furthermore, factors such as gender, cerebral blood flow, body temperature and glycemic status may influence 
stroke mechanism and outcomes associated with therapy.6,9–11  
 
Glucagon Like Peptide-1 (GLP-1) receptor agonists are gaining increasing momentum as possible neuroprotective 
agents in AIS. GLP-1 is an incretin hormone. Alongside its role in insulin secretion from the pancreas and 
glucagon suppression, it also crosses the blood-brain barrier (BBB) and promotes synaptic function, enhances 
neurogenesis, reduces apoptosis and protects neurons from oxidative stress.12 GLP-1 is produced in the brain and 
receptors are distributed throughout the central nervous system.13 GLP-1 Receptor Agonists (GLP-1RAs), 
licensed for Type 2 Diabetes Mellitus (T2DM) have already demonstrated pre-clinical neuroprotective efficacy 
in Alzheimer’s Disease and clinical trials in neurodegenerative conditions are ongoing.12,14  
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The aim of this systematic scoping review is to report the pre-clinical basis of GLP-1RAs as neuroprotective 
agents in AIS and their translation into clinical trials. As well as describing the characteristics and quality of 
studies, objectives are to specifically consider timing of administration, association with glycemic status, 
neuroprotective outcomes and application to clinical care. 
 
Materials and Methods:  
Eligibility criteria: 
Pre-clinical: We included pre-clinical in vivo studies which administered naturally occurring GLP-1, a mimetic 
or analogue, before, during or after stroke induction. Normoglycemic, hyperglycemic and induced T2DM models 
were included.  
 
Studies were excluded if their only focus was hemorrhagic stroke as this does not reflect the proposed mechanism 
for how GLP-1 is involved in ischemic tissue injury. Those studies which reported incidence of hemorrhagic 
transformation as a complication of AIS were included as these reflect post-stroke complications. 
 
Clinical: We included all prospective clinical trials which administered GLP-1RAs before, during or after stroke 
onset with outcome measures defined to identify neuroprotective efficacy by way of stroke volume reduction or 
improvement in post-stroke function or mortality. We also included any potential feasibility or safety-based 
studies in this area.  
 
Our scoping searches identified that only a small quantity of prospective clinical trials measuring stroke 
outcomes were available. Pragmatically, we therefore also included all retrospective database analyses of stroke 
incidence or composite cardiovascular outcomes in patients treated with GLP-1RAs. Furthermore, we included 
cardiovascular outcome trials (CVOTs) of GLP-1RAs to evaluate the incidence of stroke in this relatively 
higher risk cohort. 
 
Studies were excluded if their full-text was not available or not published in English. Efforts were made to 
contact authors directly to obtain any missing articles or data.  
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Database search strategy:  
After several initial scoping searches15, we accessed Web of Science on 19/3/2020 to search MEDLINE, Web of 
Science core collection, BIOSIS and SciELO from 1/1/2000. Keywords were EITHER ‘GLP(-)1, glucagon like 
peptide(-)1, exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, semaglutide’ AND EITHER ‘stroke, 
CVA, cerebrovascular, h(a)emorrhage, small vessel disease’. Articles were cross-referenced and references were 
searched to identify further studies of interest.  
 
All articles/studies were screened independently in an unblinded, standardised manner by MM and HE by way of 
title and abstract to identify those suitable for full-text review. Queries and disagreements were resolved by 
discussion. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were 
applied. Pre-clinical studies were appraised according to Animal Research: Reporting of In Vivo Experiments 
(ARRIVE) guidelines,16 and the updated Stroke Therapy Academic Industry Roundtable Preclinical 
Recommendations (STAIR) guidelines.7 Data supporting the findings of this review are available from the 
corresponding author upon reasonable request. 
 
Results:  
Study selection: 
The literature search identified 797 results (see Fig.1) alongside 10 from other sources. After removal of 
duplicates this left 794 for screening. We excluded 593 articles based upon title and review of abstract leaving 
201 full text articles to review. In total, 35 preclinical studies, 11 retrospective database studies, 7 cardiovascular 
outcome trials and 4 prospective clinical studies met the inclusion criteria.  
 
Pre-clinical studies:  
Characteristics of included studies: 
As shown in Table 1, 35 pre-clinical studies were included within this review. Studies were completed between 
2009 and 2020. Studies were predominantly based upon mouse and rat models of stroke, however, 1 study 
utilised a gerbil model.17 Stroke induction was either via transient (range 30 – 120 mins) or permanent common 
carotid (CCAO) or middle cerebral artery occlusion (MCAO). Most studies induced unilateral occlusion in 
keeping with spontaneously occurring stroke onset in humans, but 6 studies utilised a bilateral occlusion model. 
Cerebral ischemia was induced by either ligation, filament occlusion or ablation of the relevant artery.  
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Twelve studies administered exendin-4,17–28 9 used liraglutide,29–37 3 used rhGLP-1 (recombinant human GLP-
1),38–40 3 used lixisenatide 41–43 and 1 study each reported the utility of semaglutide,43 PEx-4 (exendin-4 loaded 
poly-microspheres),44 proGLP-1 (long acting GLP-1RA),45 DMB (GLP-1R agonist/modulator),46 dual GLP-
1/Glucose-dependent Insulinotropic Peptide (GIP) agonist (GLP-1/GIP DA) ,47 oxyntomodulin (co-activates 
GLP-1R and glucagon receptor),48 P7C3 (aminopropyl carbazole compound) 49 and one study directly compared 
exendin-4 with liraglutide.50 In 8 studies, GLP-1R antagonists, such as Ex-9-39, were administered to study the 
role of the GLP-1R in neuroprotective mechanisms.19,21–23,41,45,46,49 
 
Two studies investigated multiple doses of GLP-1RAs to compare neuroprotective efficacy and concluded that 
neuroprotection was dose-dependent.20,51 
 
Most studies administered GLP-1RAs via intraperitoneal, subcutaneous or transvenous routes. However, Zhang 
et al reported neuroprotection with both oral DMB46 and intranasal exendin-4.22   
 
Some 14 studies administered GLP-1RAs chronically prior to the onset of stroke. Clinically, this would 
represent those patients who receive GLP-1RAs as part of routine T2DM management and then go on to 
experience AIS.18,19,22,23,29,31,38,39,42,44–46,48,51 Chronic pre-treatment occurred for between 14 days prior and 15 
minutes prior to stroke onset, from 1 to 3 times daily.  
 
A further 4 studies administered GLP-1RAs prior to and following stroke onset for between 0 and 4 weeks – 
with dosing schedules of up to twice daily.17,20,21,30  
 
Most closely aligned with the proposed clinical application of administering treatment to GLP-1RA naïve 
patients in the hyper-acute AIS setting, 17 studies only administered the medication following stroke onset.24–
28,32–37,40,41,43,47,49,50 First dose was delayed between 0 minutes and 24 hours post-onset and continued for up to 4 
weeks. 
 
Alterations in physiological parameters such as body temperature have the potential to impact the outcome of 
stroke, Li et al reported no significant change in body temperature when measured before and after treatment 
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with Exendin-4.18 We did not identify any GLP-1RA study of AIS which varied temperature between groups. 
Most studies regulated body temperature within normal physiological parameters during MCAO surgery and 
animals were housed within a temperature-controlled environment.    
 
Quality of included studies: 
Pre-clinical study methodology was appraised according to the STAIR 2009 criteria, with a maximum available 
score of 7. Median score was 3 (range 2 – 7). Inclusion/exclusion criteria and reporting of potential conflicts of 
interest/funding was consistently reported in 100% and 94% of studies respectively. Fewer studies commented 
on randomisation (54%), allocation concealment (17%) and blinded assessment of outcome (43%). Only 4 
studies (11%) reported performing a sample size calculation.  
 
Reporting of pre-clinical studies was also assessed using the ARRIVE guidelines, with a maximum score of 36. 
Median score was 22 (range 14 – 29). Methods, statistical analysis, outcomes and confidence intervals were 
well reported, as were ethical and funding statements, but the justification for animal models, translation to 
human biology, limitations and adverse events were frequently not reported. 
 
Impact of hyperglycemia in stroke models: 
Twelve studies were based on hyperglycemic rodents, with or without a normoglycemic control group.  
 
Kuroki et al demonstrated that hyperglycemia was associated with an increase in infarct volume, cerebral edema 
and hemorrhagic transformation in a mouse model that underwent transient, unilateral occlusion of the MCAO 
for 60 minutes.27 They reported that intraperitoneal administration of Exendin-4 60 minutes after stroke onset 
was associated with a reduction in these parameters which was not replicated by insulin monotherapy. 
 
Briyal et al reported that liraglutide reduced infarct volume by a similar amount in both diabetic and 
normoglyemic models - but this neuroprotection was again not reproduced in the insulin treatment arm despite 
resolution of hyperglycemia.29 Deng et al further confirmed neuroprotection was independent of glycemic status 
prior to stroke onset.30 Jiang et al reported stroke infarct volume in the rhGLP-1 group was significantly reduced 
when compared to insulin treatment.38 Metformin was also shown to ameliorate hyperglycemia but did not 
confer the additional neuroprotective outcomes associated with liraglutide.31 
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One study demonstrated similar neuroprotective outcomes between 2 month old, healthy mice and 14 month 
old, overweight, diabetic mice treated with Exendin-4.25   
 
Whilst GLP-1RAs were associated with a reduction in blood glucose in hyperglycemic models,40 no study 
reported hypoglycemia when GLP-1RAs were administered to normoglycemic models. This is to be expected as 
GLP-1RA associated insulin secretion from the pancreas is glucose dependent.35 Indeed, Zhang et al concluded 
that neuroprotection was not glucose dependent.45  
 
Yang et al monitored blood glucose in rats which underwent intraperitoneal administration of semaglutide 
starting 2 hours following unilateral permanent MCAO occlusion, further demonstrating neuroprotection in the 
absence of hypoglycemic episodes.43 
 
Infarct volume and neuronal survival: 
Administration of GLP-1RAs prior to, at the point of, or delayed following stroke onset were associated with 
reduction in infarct volume. In total, 9 studies demonstrated a reduction in infarct volume with Exendin-4,18–
24,26,27 8 with liraglutide,29–33,35–37 3 with rhGLP-1, 3 with Lixisenatide and 1 with each of PEx-4, proGLP-1, 
DMB, OXM, GLP-1/GIP DA and semaglutide. Liraglutide was associated with a reduction in infarct volume 
when the first dose was delayed by up to 1 day.35 Kim et al reported a reduction in infarct volume by up to 75% 
in a rat model of transient MCAO.  Darsalia et al reported that Exendin-4 administration was associated with a 
reduction in stroke volume when administered for 4 weeks prior to, and 2-4 weeks following stroke onset.20 
However in a later study, whereby they only administered Ex-4 following stroke onset, it did not significantly 
reduce infarct volume but did reduce overall neuronal loss.25 Reduction in neuronal loss was also reported with 
semaglutide,43 rhGLP-140 and Lixisenatide.51 
 
Cellular function: 
Apoptosis represents a chain of enzymatic events resulting in programmed cell death.52 Whilst controlled 
apoptosis is essential for the maintenance of homeostasis, dysregulated apoptosis, for example in within the 
ischemic penumbra, can result in increased cell death.53 Bcl-2 is an anti-apoptotic protein which functions at 
least in part by reducing cytochrome C release from the mitochondria. Conversely, Bax is a pro-apoptotic 
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protein and increases cytochrome C levels.52 Increased Bcl-2 and reduced Bax levels, contributing to an 
increased Bcl-2:Bax ratio and representing reduced levels of apoptosis, have been reported in 3 studies of 
liraglutide29,33,37 and 1 study for each pro-GLP-1,45 rhGLP-1,39 DMB,22 Ex-4,50 Lixisenatide,51 GLP-1/GIP DA47 
and semaglutide.43 Critically, this reduction of apoptosis was reproduced in normoglycemic models when 
administered after stroke onset.33,37,43,47  
 
Caspase proteins are also pro-apoptotic and increased levels are associated with higher rates of cell death.54 
Liraglutide, Exendin-4, Lixisenatide, rhGLP-1 and semaglutide have been shown to reduce levels of caspase-3 
in pre-clinical models of stroke.33,37,39,41–43,46,50,51 Zhu et al have also demonstrated reduced levels of caspase 8 
and 9 in models administered liraglutide.33  
 
Cleavage of PARP by caspases is a signal of apoptosis and has been implicated in cerebral ischemia.53 
Reduction in PARP has been demonstrated with both liraglutide and exendin-4 treatment.33,50 
 
TUNEL assays detect DNA degradation during the later stages of apoptosis and have demonstrated reduced 
apoptotic activity with liraglutide and exendin-4.37,50,55  
 
GLP-1RA administration following stroke induction has been associated with an anti-inflammatory effect.26 
Tumor necrosis factor alpha (TNF-) is a cytokine synthesised by many cell lines – but particularly by 
macrophages and microglia.56 TNF- is involved with the inflammatory response following stroke onset.56 Five 
studies reported a reduction in TNF- when compared to controls, 3 with lixisenatide41,42,51 and 1 with each of 
liraglutide37 and exendin-4.27 Indeed, two studies reported reduced microglial activation17,24 whilst a further 
study by Darsalia et al reported reduced microglial infiltration – but a marginal effect on activation.20 Reduced 
levels of other markers of inflammation, such as myeloperoxidase and interleukin, have also been 
reported.30,37,51 
 
One study reported a non-statistically significant reduction in pro-inflammatory markers.25 
 
There is also deterioration in markers of oxidative stress following AIS. Twelve studies reported an 
improvement oxidative stress parameters following GLP-1RA administration in AIS – 5 studies of exendin-
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4,19,24,26,27,50 4 studies of liraglutide,29,30,32,36 2 of lixisenatide41,42 and 1 of rhGLP.40 Predominantly, studies 
reported reduced levels of malondialdehyde and increased concentrations glutathione and superoxide dismutase. 
 
Dong et al performed 18-FDG PET imaging in a rat model of unilateral transient MCAO. In the animals treated 
with subcutaneous liraglutide there was radiological evidence of increased glucose metabolism within the 
ischemic penumbra.34  
 
Neurovascular function: 
The neurovascular unit incorporates both cellular and extracellular components involved in the regulation of 
cerebral blood flow and blood-brain barrier function – it is involved with the maintenance of cerebral 
homeostasis and control of cerebral blood flow.57  
 
GLP-1RAs have been shown to increase cerebral blood flow following AIS when compared with controls.44 Li 
et al reported that cerebral microcirculation is reduced following AIS, but improved to a similar degree within 
4-12 hours after MCAO in diabetic mice treated with either liraglutide or exendin-4 after stroke induction.50 
Blood-brain barrier integrity has also been shown to improve with GLP-1RA treatment.26 
 
Vascular endothelial growth factor (VEGF) is known to promote angiogenesis and protect ischemic neurons 
from injury – demonstrating a crucial role in the neurovascular remodelling post-AIS.58 Chen et al demonstrated 
that intraperitoneal liraglutide therapy, administered 24 hours following stroke induction and once daily for 14 
days, was associated with increased VEGF expression when compared with normal saline treatment at days 7 
and 14 post-AIS in a normoglycemic model.35 Similarly, Sato et al demonstrated upregulation of VEGF in the 
cerebral cortex of liraglutide treated, normoglycemic rats, however, this was not seen within the striatum.32 
 
Markers of neuronal, glial and endothelial function (NeuN, GFAP and vWF respectively) were used by Dong et 
al to investigate for evidence of neurovascular remodelling following AIS. They reported that liraglutide, 
administered to normoglycemic mice at 1 and 24 hours following bilateral, transient CCAO, was associated 
with significantly higher levels of each marker – indicating increased remodelling associated with GLP-1RAs 
following AIS.34 
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Jiang et al reported that levels of brain injury markers (S100B, NSE and MBP) were reduced with both rhGLP-1 
and nimodipine treatments.38  
 
Wang et al investigated for evidence of increased neurogenesis associated with GLP-1R activation. They 
reported that doublecortin (marker of newborn neuroblasts) and -tubulin III (marker of neurogenesis and neural 
progenitor activity) levels were significantly upregulated with P7C3 treatment when compared to controls. They 
also report increased levels of cell proliferation markers (ki67, BrdU) and neurodevelopmental markers 
(adam11, adamts20) alongside markers of increased neurogenesis (GSK-3 inhibition).49  
 
Darsalia et al also counted ki67 expressing cells to evaluate stem cell proliferation and reported a 2-fold greater 
number of proliferating cells in the exendin-4 treatment group compared with controls at 2 weeks following 
stroke induction – however, there was no detectable difference at 4 weeks. Doublecortin levels were also 
increased at 2 weeks in the exendin-4 treatment group, with no difference from controls at 4 weeks. When using 
Neun and BrdU expressing neurons to identify new, mature neurons generated after stroke onset there was no 
difference between the treatment and control groups. 
 
Doublecortin levels were also shown to be increased with semaglutide treatment.43  
 
Neurological outcomes: 
Assessment of neurological outcomes was heterogeneous amongst studies, with many utilising a range of 
different techniques or modified adaptions. Overall, selected neurological assessments examined both cognitive 
and locomotive neurological function.  
 
Eight studies reported a reduction in post-stroke neurological deficit when treated with liraglutide,29,31–36,50 6 
with exendin-4,17–19,22,23,26 2 with rhGLP-1,38,39 2 with lixisenatide41,42 and 1 study for each of PEx-4,44 proGLP-
1,45 DMB,46 OXM,50 GLP-1/GIP DA,47 P7C349 and semaglutide.43 
 
Nine studies reported a reduction in neurological deficit when GLP-1RAs were administered to normoglycemic 
models at least 1 hour after induction of AIS.32–36,41,43,47,49 
 
 12 
Notably, Filchenko et al reported that whilst reduction in neurological deficit was observed in the non-diabetic 
rat model treated with liraglutide, this trend was not observed in the diabetic groups.31 
 
Potential mechanisms: 
GLP-1RAs stimulate insulin secretion from the pancreas in a glucose-dependent manner. Neuroprotective 
efficacy has been demonstrated in both diabetic and normoglycemic models; their neuroprotection is therefore 
not glucose-dependent.27,31,45 
 
Whilst it is well documented that GLP-1R levels increase following AIS, the precise mechanism of 
neuroprotection is not completely understood. These have been broadly summarised in Fig.2, reflecting the 
direct and indirect potential mechanisms. To further understand the role of the GLP-1R, studies have utilised 
targeted GLP-1R shRNA and the GLP-1R antagonist, Ex-9-39. GLP-1R targeted shRNA has been reported to 
block the neuroprotective efficacy of GLP-1RAs.22,45,46 However, whilst there are some reports of Ex-3-9 
administration blocking neuroprotection,21 suggestive of GLP-1R dependence, other studies did not 
demonstrated this trend – highlighting the possibility of a GLP-1R independent mechanism.41,46  For example, 
GLP-1 [28-36] is cleaved from endogenous GLP-1; research has shown this cell-permeable nonapeptide to have 
antioxidant, anti-apoptotic and mitochondrial regulatory properties in pancreatic cells – further research is 
required to establish its role in neural tissue 59. 
 
The reduction in apoptosis, oxidative stress and inflammation, alongside increased neurogenesis, angiogenesis 
and cerebral blood flow are likely to contribute to the neuroprotective outcomes.  Multiple signalling cascades 
have been studied, with P-Akt/p-eNOS,44,50 cAMP/PKA22,45,46,49 and P13k/Akt22,26,33,37,45 pathways implicated in 
neuroprotection. 
 
Clinical studies: 
Stroke risk in cardiovascular outcome (safety) Trials: 
All 6 licensed GLP-1RAs (Table 2) have reported Cardiovascular Outcome Trials (CVOTs). SUSTAIN-6 
(semaglutide) and REWIND (dulaglutide) demonstrated a significant reduction in stroke incidence, HR 0.61 (95% 
CI 0.38 - 0.99, p=0.04) and HR 0.76 (95% CI 0.61 - 0.94, p=0.017) respectively. LEADER (liraglutide) reported 
a non-statistically significant reduction in non-fatal stroke incidence, HR 0.89 (95% CI 0.72 - 1.11, p=0.30). This 
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was not reported in ELIXA (lixisenatide), EXSCEL (exenatide), HARMONY (albiglutide) and notably not in the 
oral semaglutide study, PIONEER-6. 
 
Gerstein et al have recently further analysed the REWIND trial. They report that participants who experienced 
stroke during follow up were categorised as either ischemic, hemorrhagic or undetermined and a modified Rankin 
scale (mRS) was recorded to assess severity. Whilst dulaglutide reduced the incidence of ischaemic stroke, it did 
not affect stroke severity.60  
 
Post-hoc analysis of CVOT trial data has identified sub-groups which may potentially derive greater 
cardiovascular protection. Mann et al identified enhanced benefits in patients with chronic kidney disease 61, 
whilst Kang et al reported increased benefit in Asian participants.62 
 
Meta-analysis by Barkas et al 63 demonstrated a 13% reduction in the risk of total stroke associated with GLP-
1RA treatment versus placebo (RR 0.87, 95% CI 0.78–0.98, p=0.021).  
 
GLP-1RAs and stroke in real-world datasets 
We identified 11 published retrospective studies analysing cardiovascular outcomes of T2DM patients who had 
been treated with GLP-1RAs (Table 3). These were conducted using data extracted from insurance/national 
databases.  
 
Recently, O’Brien et al (2018) reported a retrospective cohort study of 132,737 insured adults with T2DM 
commenced on a second line diabetes medication between 2011 and 2015 64. Adjusting for confounding variables, 
GLP-1RAs were associated with a reduction in stroke risk (HR 0.65, 95% CI 0.44-0.97) when compared to 
treatment with Dipeptidyl Peptidase-4 (DPP-4) inhibitors. Reduction in stroke risk was reported in a further 2 
studies65,66 – however both Svantstrom et al and Anyanwagu et al did not report this trend.67,68 
 
Raparelli et al reported an increased GLP-1RA associated reduction in cardiovascular risk in females compared 
to males.69 
 
Prospective interventional studies: 
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Daly et al report the first pilot, non-randomised interventional study administering exenatide to 11 patients within 
12 hours of stroke onset followed by twice-daily injections until discharge 70. Glucose levels were monitored, 
followed by a 3-month modified Rankin score. Although mild nausea and vomiting were common, they reported 
no serious adverse events nor associated hypoglycemic episodes. They concluded that exenatide was safe and 
tolerable in AIS patients and did not worsen functional or neurological outcome. This study was not sufficiently 
powered to assess for improvement in stroke outcomes. 
 
Larsson et al report on PROLOGUES, a randomised controlled trial comparing pre-hospital administration of 
exenatide with standard care for hyperglycemia in patients with suspected stroke 71. Nineteen patients were 
randomised, of an intended 42, with 8 receiving exenatide. The trial was stopped early due to slow inclusion; due 
to baseline glucose criteria and obtaining informed consent. No associated adverse events were reported. 
 
Results are awaited for two prospective studies.  The Short-Term EXenatide in Acute ischemic Stroke (STEXAS) 
trial 72 is a randomised, open-label, parallel-group pilot study to investigate the efficacy of exenatide in lowering 
blood glucose levels in patients with AIS and hyperglycemia. They plan to recruit 30 patients with AIS to either 
insulin or exenatide for up to 72 hours. They will assess feasibility of administration, incidence of hypoglycemia 
and functional outcomes at 3 months. 
 
The Treatment with EXenatide in Acute Ischemic Stroke (TEXAIS) trial 73 is a 3 year, phase 2, multi-centre, 
prospective, randomised, open-label, blinded end-point trial comparing exenatide to standard care and aims to be 
powered to detect a change in neurological outcome. Primary end-point is defined as major neurological 
improvement at 7 days (8 point improvement in NIHSS score, or score 0-1). In contrast to STEXAS, this study 
will include patients independent of their glycemic status.  
 
Discussion:  
As survival following stroke increases, so does the impact of post-stroke disability. Alongside the ongoing 
development in reperfusion therapies as part of the gold standard of stroke care, a safe, widely applicable, well 
tolerated and cost-effective neuroprotective agent becomes increasingly attractive.  
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We report a systematic review of the pre-clinical research to support the neuroprotective properties of GLP-
1RAs targeting the ischemic-reperfusion injury in animal models of AIS. These have been shown to be safe and 
effective in normoglycemic models and demonstrate neuroprotective outcomes by way of reduced infarct 
volume, apoptosis, oxidative stress, inflammation and increased neurogenesis, angiogenesis and cerebral blood 
flow. Crucially, they have demonstrated an improvement in post-stroke functional outcomes – including within 
both locomotive and cognitive domains. 
 
In keeping with the real-world potential of GLP-1RAs as a neuroprotectant in the management of AIS, pre-
clinical trials have now demonstrated reproducible benefits in normoglycemic models with delayed 
administration up to 24 hours after stroke induction.  
 
Their neuroprotective mechanism is not fully understood, with further research required. However, emerging 
trends towards both GLP-1R dependent, and independent, pathways have been reported. Following direct 
comparison studies with metformin and insulin, their effects are due to more than restoration of glucose 
homeostasis. Additional research is required to fully understand the role of cleaved GLP-1 subunits, including 
GLP-1 [28-36] and could go some way to explain the difference in stroke reduction between GLP-1RAs in 
CVOTs.  
 
The economic benefits of repurposing existing treatments should not be overlooked. Especially as the CVOTs 
have demonstrated their cardiovascular safety, alongside a reduced incidence of non-fatal stroke. Retrospective 
database studies show a trend towards a reduction in cardiovascular events – providing an important perspective 
from ‘real-world’ usage. 
 
Prospective clinical trials of GLP-1RAs in stroke are ongoing, with initial outcomes suggestive of safety, 
tolerability and that GLP-1RAs are feasibly administered in the AIS cohort.  
 
The comparative effectiveness of reduction in overall cardiovascular risk with newer antidiabetic treatments, 
such as GLP-1RAs, sodium-glucose co-transporter-2 (SGLT-2) inhibitors and DPP-4 inhibitors is unclear. 
However, a recent network meta-analysis has shown that only GLP-1RAs reduced non-fatal stroke incidence 
(OR 0.88, 95% CI 0.77 – 0.99).74 
 16 
 
 
We acknowledge the limitations of this study. Pre-clinical studies were generally conducted on a homogenous 
population of young animals without representing the co-morbidities often afflicting the human stroke 
population. However, one study did demonstrate comparable neuroprotective outcomes in both young mice and 
older, obese, diabetic models.25  
 
Further research into the impact of factors such as age, hypertension and gender is required. In addition, studies 
relied on a uniform etiology of stroke onset, vascular territory and duration of occlusion – constants which are 
not representative of the diverse, heterogenous clinical manifestation of AIS. However, the inter-study 
differences in stroke induction protocols (e.g. unilateral vs. bilateral, duration and vessel occlusion) do provide 
some mitigation to this. Furthermore, some studies utilised simultaneous bilateral occlusion of the carotid 
arteries to cause global ischemia which would not normally occur in human stroke; however, this does still 
provide a valuable model of ischemic injury.  
 
We also acknowledge the effect of publication bias favouring positive outcome and the limitations presented by 
the results of our STAIR and ARRIVE assessments. The potential for under-powered research is appreciated. 
 
Overall, pre-clinical studies are restricted by small numbers, limited standardisation, disparity between study 
dose and the licensed clinical dose and having a limited ability to replicate the numerous confounding variables 
encountered in real-world stroke practice.  
 
Of course, CVOTs report stroke incidence rather than stroke outcome. Other limitations include short trial 
duration, complex multi-morbid patient characteristics, and the potential for pharmacological interactions with 
concomitant medications affecting outcomes. GLP-1RAs are known to reduce blood pressure, body weight and 
cholesterol, all potentially mitigating stroke risk. Analysis of strokes occurring within the REWIND trial 
demonstrated a reduction in stroke incidence, but no impact on stroke severity as measured by mRS. 
 
Retrospective studies generally included large numbers and are based upon real-world use and adherence. They 
reported encouraging results; often demonstrating a reduction in cardiovascular risk and/or a modest reduction 
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in stroke risk. Eloquent attempts were often made to adjust for confounding variables; but these do remain a 
significant limitation, as does incomplete extraction of events from databases 66. These studies are also limited 
by heterogeneity in treatment duration, dose, and by the grouping together of GLP-1RAs.  
 
There remains an unfulfilled requirement for neuroprotective agents in the management of AIS. Ultimately, 
many agents have previously failed to translate from bench to bedside. 
 
However, we propose that further research into the repurposing GLP-1RAs – already licensed, with established 
side effect profiles, cardiovascular safety record and clear indicators from pre-clinical research of their 
functional benefit - is both potentially clinically and economically advantageous.  Further research is required to 
establish optimal dosing, cost-effectiveness, interaction with reperfusion therapies, timing of administration, and 
to fully understand the underlying mechanism of action – with consideration of age, gender and co-morbidity - 
in order to guide larger clinical trial development. 
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Figure Legends: 
Fig.1: PRISMA flow chart demonstrating the selection of studies 
 
Fig.2: Proposed neuroprotective mechanism of action for GLP-1RAs in AIS. Direct GLP-1R activation by 
GLP-1RA. 2. Potential indirect receptor activation by GLP-1RA. 3. GLP-1 sub-units are cell permeable and 
may affect mitochondrial function, or act on extra-cellular receptors. 4. GLP-1RAs reduce excitotoxicity 
 
References: 
1  Feigin VL, Norrving B, Mensah GA. Global Burden of Stroke. Circ Res 2017; 120: 439–448. 
2  Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA et al. Global and 
regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. The 
Lancet 2014; 383: 245–255. 
3  McMeekin P, White P, James MA, Price CI, Flynn D, Ford GA. Estimating the number of UK stroke 
patients eligible for endovascular thrombectomy. Eur Stroke J 2017; 2: 319–326. 
4  Goyal M, Menon BK, van Zwam WH, Dippel DWJ, Mitchell PJ, Demchuk AM et al. Endovascular 
thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five 
randomised trials. The Lancet 2016; 387: 1723–1731. 
5  Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane 
Database Syst Rev 2014. doi:10.1002/14651858.CD000213.pub3. 
6  Neuhaus AA, Couch Y, Hadley G, Buchan AM. Neuroprotection in stroke: the importance of collaboration 
and reproducibility. Brain 2017; 140: 2079–2092. 
7  Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI et al. Update of the Stroke Therapy 
Academic Industry Roundtable Preclinical Recommendations. Stroke 2009; 40: 2244–2250. 
8  Shi S, Mörike K, Klotz U. The clinical implications of ageing for rational drug therapy. Eur J Clin 
Pharmacol 2008; 64: 183–199. 
9  Hurn PD, Vannucci SJ, Hagberg H. Adult or Perinatal Brain Injury: Does Sex Matter? Stroke 2005; 36: 
193–195. 
 19 
10  O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 Experimental 
treatments in acute stroke. Ann Neurol 2006; 59: 467–477. 
11  Sutherland BA, Minnerup J, Balami JS, Arba F, Buchan AM, Kleinschnitz C. Neuroprotection for 
Ischaemic Stroke: Translation from the Bench to the Bedside. Int J Stroke 2012; 7: 407–418. 
12  Hölscher C. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs 2012; 26: 
871–882. 
13  Gallwitz B. Extra-pancreatic effects of incretin-based therapies. Endocrine 2014; 47: 360–371. 
14  Hölscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J 
Endocrinol 2014; 221: T31–T41. 
15  Boland A, Cherry G, Dickson R. Doing a Systematic Review: A Student’s Guide. 1st ed. Sage Publications: 
London, 2013. 
16  Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving Bioscience Research Reporting: 
The ARRIVE Guidelines for Reporting Animal Research. PLoS Biol 2010; 8: e1000412. 
17  Hyun Lee C, Yan B, Yoo K-Y, Choi JH, Kwon S-H, Her S et al. Ischemia-induced changes in glucagon-
like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient 
cerebral ischemia. J Neurosci Res 2011; 89: 1103–1113. 
18  Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW et al. GLP-1 receptor stimulation 
preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and 
Parkinsonism. Proc Natl Acad Sci 2009; 106: 1285–1290. 
19  Briyal S, Gulati K, Gulati A. Repeated administration of exendin-4 reduces focal cerebral ischemia-induced 
infarction in rats. Brain Res 2012; 1427: 23–34. 
20  Darsalia V, Mansouri S, Ortsäter H, Olverling A, Nozadze N, Kappe C et al. Glucagon-like peptide-1 
receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clin Sci 2012; 
122: 473–483. 
 20 
21  Jia Y, Gong N, Li T-F, Zhu B, Wang Y-X. Peptidic exenatide and herbal catalpol mediate neuroprotection 
via the hippocampal GLP-1 receptor/β-endorphin pathway. Pharmacol Res 2015; 102: 276–285. 
22  Zhang H, Meng J, Zhou S, Liu Y, Qu D, Wang L et al. Intranasal Delivery of Exendin-4 Confers 
Neuroprotective Effect Against Cerebral Ischemia in Mice. AAPS J 2016; 18: 385–394. 
23  Kim S, Jeong J, Jung H-S, Kim B, Kim Y-E, Lim D-S et al. Anti-inflammatory Effect of Glucagon Like 
Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1/JIP1 Expression and JNK Signaling in 
Stroke. Exp Neurobiol 2017; 26: 227. 
24  Teramoto S, Miyamoto N, Yatomi K, Tanaka Y, Oishi H, Arai H et al. Exendin-4, a glucagon-like peptide-
1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow 
Metab 2011; 31: 1696–1705. 
25  Darsalia V, Hua S, Larsson M, Mallard C, Nathanson D, Nyström T et al. Exendin-4 Reduces Ischemic 
Brain Injury in Normal and Aged Type 2 Diabetic Mice and Promotes Microglial M2 Polarization. PLoS 
ONE 2014; 9: e103114. 
26  Chen F, Wang W, Ding H, Yang Q, Dong Q, Cui M. The glucagon-like peptide-1 receptor agonist exendin-
4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia. J 
Neuroinflammation 2016; 13. doi:10.1186/s12974-016-0661-0. 
27  Kuroki T, Tanaka R, Shimada Y, Yamashiro K, Ueno Y, Shimura H et al. Exendin-4 inhibits matrix 
metalloproteinase-9 activation and reduces infarct growth after focal cerebral ischemia in hyperglycemic 
mice. Stroke 2016; : STROKEAHA–116. 
28  Yang J-L, Chen W-Y, Chen Y-P, Kuo C-Y, Chen S-D. Activation of GLP-1 Receptor Enhances Neuronal 
Base Excision Repair via PI3K-AKT-Induced Expression of Apurinic/Apyrimidinic Endonuclease 1. 
Theranostics 2016; 6: 2015–2027. 
29  Briyal S, Shah S, Gulati A. Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain 
following focal cerebral ischemia. Neuroscience 2014; 281: 269–281. 
 21 
30  Deng C, Cao J, Han J, Li J, Li Z, Shi N et al. Liraglutide Activates the Nrf2/HO-1 Antioxidant Pathway 
and Protects Brain Nerve Cells against Cerebral Ischemia in Diabetic Rats. Comput Intell Neurosci 2018; 
2018: 1–7. 
31  Filchenko I, Simanenkova A, Chefu S, Kolpakova M, Vlasov T. Neuroprotective effect of glucagon-like 
peptide-1 receptor agonist is independent of glycaemia normalization in type two diabetic rats. Diab Vasc 
Dis Res 2018; 15: 567–570. 
32  Sato K, Kameda M, Yasuhara T, Agari T, Baba T, Wang F et al. Neuroprotective Effects of Liraglutide for 
Stroke Model of Rats. Int J Mol Sci 2013; 14: 21513–21524. 
33  Zhu H, Zhang Y, Shi Z, Lu D, Li T, Ding Y et al. The Neuroprotection of Liraglutide Against Ischaemia-
induced Apoptosis through the Activation of the PI3K/AKT and MAPK Pathways. Sci Rep 2016; 6. 
doi:10.1038/srep26859. 
34  Dong W, Miao Y, Chen A, Cheng M, Ye X, Song F et al. Delayed administration of the GLP-1 receptor 
agonist liraglutide improves metabolic and functional recovery after cerebral ischemia in rats. Neurosci Lett 
2017; 641: 1–7. 
35  Chen Y, Zhang X, He J, Xie Y, Yang Y. Delayed Administration of the Glucagon-Like Peptide 1 Analog 
Liraglutide Promoting Angiogenesis after Focal Cerebral Ischemia in Mice. J Stroke Cerebrovasc Dis 
2018; 27: 1318–1325. 
36  He W, Wang H, Zhao C, Tian X, Li L, Wang H. Role of liraglutide in brain repair promotion through Sirt1‐
mediated mitochondrial improvement in stroke. J Cell Physiol 2020; 235: 2986–3001. 
37  Zeng S, Bai J, Jiang H, Zhu J, Fu C, He M et al. Treatment With Liraglutide Exerts Neuroprotection After 
Hypoxic–Ischemic Brain Injury in Neonatal Rats via the PI3K/AKT/GSK3β Pathway. Front Cell Neurosci 
2020; 13. doi:10.3389/fncel.2019.00585. 
38  Jiang D, Wang Y, Zang Y, Liu X, Zhao L, Wang Q et al. Neuroprotective Effects of rhGLP-1 in Diabetic 
Rats with Cerebral Ischemia/Reperfusion Injury: rhGLP-1 NEUROPROTECTIVE BENEFITS. Drug Dev 
Res 2016; 77: 124–133. 
 22 
39  Fang Y, Jiang D, Wang Y, Wang Q, Lv D, Liu J et al. Neuroprotection of rhGLP-1 in diabetic rats with 
cerebral ischemia/reperfusion injury via regulation of oxidative stress, EAAT2, and apoptosis. Drug Dev 
Res 2018; 79: 249–259. 
40  Zhao L, Xu J, Wang Q, Qian Z, Feng W, Yin X et al. Protective effect of rhGLP-1 (7–36) on brain 
ischemia/reperfusion damage in diabetic rats. Brain Res 2015; 1602: 153–159. 
41  Abdel-latif RG, Heeba GH, Taye A, Khalifa MMA. Lixisenatide ameliorates cerebral ischemia-reperfusion 
injury via GLP-1 receptor dependent/independent pathways. Eur J Pharmacol 2018; 833: 145–154. 
42  Abdel-latif RG, Heeba GH, Taye A, Khalifa MMA. Lixisenatide, a novel GLP-1 analog, protects against 
cerebral ischemia/reperfusion injury in diabetic rats. Naunyn Schmiedebergs Arch Pharmacol 2018; 391: 
705–717. 
43  Yang X, Feng P, Zhang X, Li D, Wang R, Ji C et al. The diabetes drug semaglutide reduces infarct size, 
inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke. Neuropharmacology 
2019; 158: 107748. 
44  Chien C-T, Jou M-J, Cheng T-Y, Yang C-H, Yu T-Y, Li P-C. Exendin-4-loaded PLGA microspheres 
relieve cerebral ischemia/reperfusion injury and neurologic deficits through long-lasting bioactivity-
mediated phosphorylated Akt/eNOS signaling in rats. J Cereb Blood Flow Metab 2015; 35: 1790–1803. 
45  Zhang H, Meng J, Li X, Zhou S, Qu D, Wang N et al. Pro-GLP-1, a Pro-drug of GLP-1, is neuroprotective 
in cerebral ischemia. Eur J Pharm Sci 2015; 70: 82–91. 
46  Zhang H, Liu Y, Guan S, Qu D, Wang L, Wang X et al. An Orally Active Allosteric GLP-1 Receptor 
Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke. PLOS ONE 2016; 11: e0148827. 
47  Han L, Holscher C, Xue G, Li G, Li D. A novel dual-glucagon-like peptide 1 and glucose-dependent 
insulinotrophic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischaemia in the 
rat. Neuroreport 2016; 6: 23–32. 
48  Li Y, Wu K-J, Yu S-J, Tamargo IA, Wang Y, Greig NH. Neurotrophic and neuroprotective effects of 
oxyntomodulin in neuronal cells and a rat model of stroke. Exp Neurol 2017; 288: 104–113. 
 23 
49  Wang Y-H, Liou K-T, Tsai K-C, Liu H-K, Yang L-M, Chern C-M et al. GSK-3 inhibition through GLP-1R 
allosteric activation mediates the neurogenesis promoting effect of P7C3 after cerebral 
ischemic/reperfusional injury in mice. Toxicol Appl Pharmacol 2018; 357: 88–105. 
50  Li P-C, Liu L-F, Jou M-J, Wang H-K. The GLP-1 receptor agonists exendin-4 and liraglutide alleviate 
oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in 
diabetic mice. BMC Neurosci 2016; 17. doi:10.1186/s12868-016-0272-9. 
51  Gad SN, Nofal S, Raafat EM, Ahmed AAE. Lixisenatide Reduced Damage in Hippocampus CA1 Neurons 
in a Rat Model of Cerebral Ischemia-Reperfusion Possibly Via the ERK/P38 Signaling Pathway. J Mol 
Neurosci 2020. doi:10.1007/s12031-020-01497-9. 
52  Pawlowski J, Kraft AS. Bax-induced apoptotic cell death. Proc Natl Acad Sci 2000; 97: 529–531. 
53  Chaitanya G, Alexander JS, Babu P. PARP-1 cleavage fragments: signatures of cell-death proteases in 
neurodegeneration. Cell Commun Signal 2010; 8: 31. 
54  Porter AG, Jänicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ 1999; 6: 99–104. 
55  Darzynkiewicz Z, Galkowski D, Zhao H. Analysis of apoptosis by cytometry using TUNEL assay. 
Methods 2008; 44: 250–254. 
56  Wilkins HM, Swerdlow RH. TNFα in cerebral ischemia: another stroke against you? J Neurochem 2015; 
132: 369–372. 
57  Bell AH, Miller SL, Castillo-Melendez M, Malhotra A. The Neurovascular Unit: Effects of Brain Insults 
During the Perinatal Period. Front Neurosci 2020; 13. doi:10.3389/fnins.2019.01452. 
58  Ma Y, Zechariah A, Qu Y, Hermann DM. Effects of vascular endothelial growth factor in ischemic stroke. 
J Neurosci Res 2012; 90: 1873–1882. 
59  Zhou B, Ji K, Peng A, Yang X, Huang K. GLP-1(28-36)amide, a Long Ignored Peptide Revisited. Open 
Biochem J 2014; 8: 107–111. 
60  Gerstein HC, Hart R, Colhoun HM, Diaz R, Lakshmanan M, Botros FT et al. The effect of dulaglutide on 
stroke: an exploratory analysis of the REWIND trial. Lancet Diabetes Endocrinol 2020; 8: 106–114. 
 24 
61  Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T et al. Effects of Liraglutide Versus 
Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: 
Results From the LEADER Trial. Circulation 2018; 138: 2908–2918. 
62  Kang YM, Cho YK, Lee J, Lee SE, Lee WJ, Park J-Y et al. Asian Subpopulations May Exhibit Greater 
Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis 
of Cardiovascular Outcome Trials. Diabetes Metab J 2018; 42. doi:10.4093/dmj.2018.0070. 
63  Barkas F, Elisaf M, Milionis H. Protection against stroke with glucagon-like peptide 1 receptor agonists: a 
systematic review and meta-analysis. Eur J Neurol 2019. doi:10.1111/ene.13905. 
64  O’Brien MJ, Karam SL, Wallia A, Kang RH, Cooper AJ, Lancki N et al. Association of Second-line 
Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes. JAMA 
Netw Open 2018; 1: e186125. 
65  Paul SK, Klein K, Maggs D, Best JH. The association of the treatment with glucagon-like peptide-1 
receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a 
retrospective observational study. Cardiovasc Diabetol 2015; 14: 10. 
66  Zimmerman RS, Hobbs TM, Wells BJ, Kong SX, Kattan MW, Bouchard J et al. Association of glucagon-
like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in 
patients with type 2 diabetes mellitus in a large integrated health system. Diabetes Obes Metab 2017; 19: 
1555–1561. 
67  Svanström H, Ueda P, Melbye M, Eliasson B, Svensson A-M, Franzén S. Use of liraglutide and risk of 
major cardiovascular events: a register based cohort study in Denmark and Sweden. Lancet Diabetes 
Endocrinol 2019; 7: 106–114. 
68  Anyanwagu U, Mamza J, Mehta R, Donnelly R, Idris I. Cardiovascular events and all-cause mortality with 
insulin versus glucagon-like peptide-1 analogue in type 2 diabetes. Heart 2016; 102: 1581–1587. 
69  Raparelli V, Elharram M, Moura CS, Abrahamowicz M, Bernatsky S, Behlouli H et al. Sex Differences in 
Cardiovascular Effectiveness of Newer Glucose‐Lowering Drugs Added to Metformin in Type 2 Diabetes 
Mellitus. J Am Heart Assoc 2020; 9. doi:10.1161/JAHA.119.012940. 
 25 
70  Daly SC, Chemmanam T, Loh P-S, Gilligan A, Dear AE, Simpson RW et al. Exenatide in Acute Ischemic 
Stroke. Int J Stroke 2013; 8: E44–E44. 
71  Larsson M, Castren M, Lindström V, von Euler M, Patrone C, Wahlgren N et al. Prehospital exenatide in 
hyperglycemic stroke – a randomized trial. Acta Neurol Scand 2019. doi:10.1111/ane.13166. 
72  McGrath RT, Hocking SL, Priglinger M, Day S, Herkes GK, Krause M et al. Rationale and design of 
Short-Term EXenatide therapy in Acute ischaemic Stroke (STEXAS): a randomised, open-label, parallel-
group study. BMJ Open 2016; 6: e008203. 
73  Muller C, Cheung NW, Dewey H, Churilov L, Middleton S, Thijs V et al. Treatment with exenatide in 
acute ischemic stroke trial protocol: A prospective, randomized, open label, blinded end-point study of 
exenatide vs. standard care in post stroke hyperglycemia. Int J Stroke 2018; 13: 857–862. 
74  Fei Y, Tsoi M-F, Cheung BMY. Cardiovascular outcomes in trials of new antidiabetic drug classes: a 
network meta-analysis. Cardiovasc Diabetol 2019; 18. doi:10.1186/s12933-019-0916-z. 
75  Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV et al. Lixisenatide in Patients with 
Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015; 373: 2247–2257. 
76  Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA et al. Liraglutide and 
Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311–322. 
77  Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA et al. Semaglutide and Cardiovascular 
Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 1834–1844. 
78  Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB et al. Effects of Once-Weekly 
Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377: 1228–1239. 
79  Hernandez AF, Green JB, Janmohamed S, D’Agostino Sr RB, Granger CB, Jones NP et al. Albiglutide and 
cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): 
a double-blind, randomised placebo-controlled trial. The Lancet 2018; 392: 1519–1529. 
 26 
80  Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P et al. Dulaglutide and 
cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled 
trial. The Lancet 2019; 394: 121–130. 
81  Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR et al. Oral Semaglutide 
and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2019; 381: 841–851. 
82  Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M et al. Risk of Cardiovascular 
Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) 
Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis 
of the LifeLink database. Diabetes Care 2011; 34: 90–95. 
83  Gejl M, Starup-Linde J, Scheel-Thomsen J, Gregersen S, Vestergaard P. Risk of cardiovascular disease: 
The effects of diabetes and anti-diabetic drugs — A nested case–control study. Int J Cardiol 2015; 178: 
292–296. 
84  Patorno E, Everett BM, Goldfine AB, Glynn RJ, Liu J, Gopalakrishnan C et al. Comparative cardiovascular 
safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort 
study. Diabetes Obes Metab 2016; 18: 755–765. 
85  Ekström N, Svensson A-M, Miftaraj M, Franzén S, Zethelius B, Eliasson B et al. Cardiovascular safety of 
glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the 
Swedish National Diabetes Register. Diabetes Obes Metab 2016; 18: 990–998. 
86  Anyanwagu U, Mamza J, Donnelly R, Idris I. Effect of adding GLP-1RA on mortality, cardiovascular 
events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective 
UK cohort study. Am Heart J 2018; 196: 18–27. 
87  Frison V, Simioni N, Marangoni A, Balzano S, Vinci C, Zenari L et al. Clinical Impact of 5 Years of 
Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-
Life Setting in Italy: An Observational Study. Diabetes Ther 2018; 9: 2201–2208. 
 27 
TABLE 1:     Overview of the pre-clinical studies 
Author Year Animal 
model 
Co-
morb. 
Drug Admin 
route 
Sub-studies Stroke induction 
(time/mins) 
Administration time (mins) Main outcomes (NP – Neuroprotective) 
Pre-ischemia Post-ischemia 
GLP-1RA administered prior to stroke onset (including chronic pre-treatment) 
Li18 2009 Rat  
 
Ex-4 i.c.v. 
 
u.l tMCAO (60) 15 
 
NP –  infarct volume and improves functional outcome 
Briyal19 2012 Rat  
 
Ex-4 i.p. BQ123  u.l. pMCAO  BD - 7 days 
 
NP –  infarct volume,  motor deficit,  oxidative stress parameters (MDA,  GSH,  SOD)  
NP via  oxidative stress and independent of endothelin receptor. 
Briyal29 2014 Rat DM Liraglutide s.c. Non-diabetic, insulin u.l. pMCAO  OD - 14 days 
 
NP -  infarct volume,  motor deficit,  oxidative stress parameters ( MDA,  GSH,  SOD), 
 apoptosis ( Bcl-2,  Bax).  
NP in both non-diabetic & DM models with similar infarct volume reduction, insulin treatment 
did not reduce infarct volume. NP via  oxidative stress and  apoptosis 
Chien44 2015 Rat DM PEx-4 s.c. Non-diabetic, Ex-4 b.l tCCAO (10) & 
hypotension 
OD - 14 days 
 
NP -  brain oedema,  cognitive deficit,  oxidative stress,  cerebral blood flow 
PEx-4 more NP than Ex-4 in DM. 
Zhang45 2015 Mouse 
 
Pro-GLP-1 i.p. shRNA u.l. tMCAO (90) OD - 7 days 
 
NP – infarct volume,  neurological deficit,  apoptosis ( Bcl-2,  Bax).  
NP not glucose dependent. 
NP blocked by shRNA (suggesting GLP-1R mediated NP) 
Jiang38 2016 Rat DM rhGLP-1 i.p. nimodipine, insulin u.l. tMCAO (90) TDS - 14 days 
 
NP in DM -  infarct volume (more than insulin group),  neurological deficit,  brain injury 
markers ( S100B, NSE,  MBP) 
Zhang46 2016 Mouse 
 
DMB p.o. Ex-4, Ex-9-39, 
shRNA 
u.l. tMCAO (60) 30 
 
NP given orally -  infarct volume,  neurological deficit,  apoptosis ( Bcl-2,  Bax). 
No impact on plasma insulin and glucose levels in non-diabetic mice 
DMB activation of GLP-1R different to Ex-4.  
NP blocked by shRNA but not by Ex-9-39. 
Zhang22 2016 Mouse 
 
Ex-4 i.n.  Intraperitoneal Ex-4, 
shRNA 
u.l. tMCAO (90) OD – 7 days 
 
NP given intranasally -  infarct volume,  neurological deficit,  apoptosis ( caspase-3) 
Intranasal route produced  CNS concentration than i.p. 
No impact on plasma insulin and glucose levels and NP was blocked by shRNA suggesting NP 
is GLP-1R mediated. 
Kim23 2017 Rat 
 
Ex-4 i.c,v Ex-9-39 u.l. MCAO (60) 30 
 
NP -  infarct volume (by up to 75%),  neurological deficit,  
 oxidative damage/inflammation ( COX-2,  PE2) 
Li48 2017 Rat 
 
OXM i.c.v. 
 
u.l. tMCAO (60) 15 
 
NP –  infarct volume,  locomotive activity 
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Abdel-latif42 2018 Rat DM Lixisenatide  i.p. glimepiride b.l. tCCAO (30) OD – 14 days 
 
NP -  infarct volume,  neurological deficit,  oxidative stress ( MDA,  GSH,  catalase),  
inflammation/apoptosis ( caspase-3,  TNF-) 
Lixisenatide more NP than glimepiride. 
Fang39 2018 Rat DM rhGLP-1 i.p. nimodipine u.l. tMCAO (90) TDS – 14 days 
 
NP -  infarct volume,  neurological deficit,  oxidative stress parameters ( MDA, GSH,  
SOD),  apoptosis (Bcl-2, Bax,  caspase-3), EAAT2, 
Filchenko31 2018 Rat DM Liraglutide s.c. Non-diabetic, 
metformin 
u.l. tMCAO (30) OD – 7 days  NP -  infarct volume,  neurological deficit only in non-DM model,  
NP not associated with glycemic control amelioration (Metformin not NP) 
Gad51 2020 Rat  Lixisenatide i.p. 0.7 and 7 nmol/kg 
lixisenatide  
b.l. tCCAO (60) OD - 14 days  NP -  oxidative stress parameters ( MDA, GSH,  SOD),  apoptosis (Bcl-2, Bax,  
caspase-3),  inflammatory markers ( MPO,  IL-1,  TNF-),  viable hippocampal neurons 
on histological staining. 
Higher dose Lixisenatide  NP 
GLP-1RA administered prior to and following stroke onset 
Hyun Lee17 2011 Gerbil 
 
Ex-4 i.p. 
 
b.l. tCCAO (5) 120 60 NP -  neurological deficit,  GLP-1R immunoreactivity,  microglial activation  
Darsalia20 2012 Rat DM Ex-4 i.p. 0.1, 2 or 5g/kg of 
Ex-4 
u.l. tMCAO (90) BD - 4 weeks BD – 2 - 4 
weeks 
NP -  infarct volume (no difference between 2 & 4 weeks post MCAO),  microglial 
infiltration but marginal effect on activation,  stem cell proliferation & neuroblast formation. 
NP is dose dependent. 
Jia21 2015 Rat 
 
Ex-4/Catapol i.c.v. Ex-9-39 u.l. tMCAO (60) 15 0 NP -  infarct volume,  neurological deficit,  hippocampal -endorphin expression,  
NP blocked by Ex-9-39, -endorphin anti-serum and naloxone 
Deng30 2018 Rat DM Liraglutide i.p. Non-DM u.l. pMCAO BD – 7 days BD – 7 days NP-  infarct volume,  neurological deficit,  oxidative stress ( SOD),  inflammation ( 
MPO),  Nrf2,  HO-1 (antioxidative stress signalling pathway) 
No significant difference in NP between DM & non-DM 
GLP-1RA administered following stroke onset (including delayed administration) 
Teramoto24 2011 Mouse  
 
Ex-4 t.v. 
 
u.l tMCAO (60) 
 
0/60/180 NP -  infarct volume,  neurological deficit,  oxidative stress,  inflammation ( microglial 
activation),   intracellular cAMP levels (due to GLP-1R activation). 
NP probably mediated via raised intracellular cAMP levels  
Sato32 2013 Rat 
 
Liraglutide i.p. 
 
u.l. tMCAO (90) 
 
60 NP -  infarct volume,  neurological deficit,  oxidative stress,  VEGF in cortex but not in 
the striatum. 
Darsalia25 2014 Mouse DM Ex-4 i.p. 2 month old & 14 
month obese/DM 
mice 
u.l. tMCAO (30)  90, 180 or 270 
then OD 1 week 
NP -  neuronal survival,   M2 microglial markers 
Non statistically significant reduction in pro-inflammatory markers  
NP in non-DM/DM at 50g/kg at 90/180 mins & at 90 mins for 5g/kg. 
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Stroke volume not affected by Ex-4 administration 
Not NP when Ex-4 administered 4.5hrs after stroke onset  
NP in both young and old animal models  
Zhao40 2015 Rat DM rhGLP-1 i.p. nimodipine u.l. tMCAO (120) 
 
0 NP -  infarct volume,  neuronal survival,  oxidative stress ( MDA, GSH,  SOD),  nitric 
oxide damage (iNOS, eNOS) 
Statistically significant reduction in blood glucose in high dose group (no hypoglycemia) 
Han47 2016 Rat 
 
GLP-1/GIP 
(DA) 
 
i.p. GLP-1RA (SA) u.l. tMCAO (60) 
 
60 NP -  infarct volume,  neurological deficit,  apoptosis ( Bcl-2,  Bax),  nitric oxide 
damage (iNOS) 
DA more NP than SA. 
Chen26 2016 Mouse 
 
Warfarin & 
Ex-4  
t.v. P13K inhibitor u.l. tMCAO (45) 
 
0 NP -  infarct volume,  neurological deficit, BBB integrity,  oxidative stress ( 8-OHdG, 
HHE),  inflammation,  
NP blocked by P13K inhibitor. 
Ameliorated warfarin associated hemorrhagic transformation.  
Kuroki27 2016 Mouse DM Ex-4 i.p. insulin u.l. tMCAO (60) 
 
60 Hyperglycemia associated with  infarct volume,  cerebral oedema,  hemorrhagic 
transformation.  
Ex-4 NP -  infarct volume,  cerebral oedema,  oxidative stress,  inflammation ( TNF-), 
 MMP-9 activation, Iba-1 positive microglia,  
NP in hyperglycemic model. Insulin not NP. 
Li50 2016 Mouse DM 
 
Ex-4 or 
Liraglutide  
 
i.p. 
 
u.l. tMCAO (60) 
 
0, 3, 6 or 12hrs NP -  neurological deficit including  bladder dysfunction,  cerebral microcirculation.  
cerebral oedema,  oxidative stress ( DHE,  ROS,  SOD),  apoptosis ( caspase-3,  
TUNEL, Bax, PARP,  Bcl-2),  inflammation ( ICAM-1, NF-2B, p50, p65).  
Yang28 2016 Rat 
 
Ex-4 t.v. 
 
u.l. tMCAO &  
b.l. tCCAO (60) 
 
0 & 24hrs NP –  DNA damage ( APE1,  TUNEL) 
Zhu33 2016 Rat 
 
Liraglutide s.c. 
 
u.l pMCAO 
 
1hr, then OD 
for 1, 3 and 7 
days 
NP -  infarct volume,  neurological deficit,  apoptosis ( ROS,  caspase-3, -8, -9,  PARP, 
 Bcl-2,  Bax),  DNA damage ( TUNEL),  stress related hyperglycemia without causing 
hypoglycemia.  
Dong34 2017 Rat 
 
Liraglutide s.c. 
 
u.l. MCAO (90) 
 
24hrs, then OD 
for 4 weeks 
NP -  neurological deficit,  
 GLP-1R expression 
 glucose metabolism in ischemic penumbra (18-FDG-PET) 
 neurovascular remodelling ( NeuN,  GFAP,  vWF) 
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NP when first dose delayed by 1 day 
Abdel-latif41 2018 Rat 
 
Lixisenatide  i.p. Ex-9-39, 
pentoxyphylline 
b.l. tCCAO (30) 
 
1 & 24hrs NP -  infarct volume,  neurological deficit,  apoptosis (caspase-3),  oxidative stress ( 
GSH,  MDA,  catalase, NO),  inflammation (TNF-) – these effects not inhibited by GLP-
1R antagonist Ex-39 suggesting GLP-1R independent pathway.  
Chen35 2018 Mouse 
 
Liraglutide i.p. 
 
u.l. pMCAO 
 
24hrs, then OD 
for 14 days 
NP -  infarct volume,  neurological deficit,  angiogenesis (VEGF) 
No significant difference in blood glucose levels between Liraglutide and Controls (as expected, 
stimulated insulin release is in a blood-glucose dependent manner) 
NP when first dose delayed by 1 day 
Wang49 2018 Mouse 
 
P7C3 t.v. Ex-9-39 u.l. tMCAO (40) 
 
120 NP -  neurological deficit,  neurogenesis ( doublecortin,  -tub3,  adam11,  adamts20,  
GSK-3) 
NP is GLP-1R dependent. 
Yang43 2019 Rat  Semaglutide i.p. Blood glucose 
monitoring 
u.l. pMCAO  2hrs, then 
alternate days 
1,7,14 or 21 
days 
NP -  infarct volume,  neurological deficit,  neuronal loss,  apoptosis (Bcl-2, Bax,  
caspase-3),  neurogenesis, improved growth factor signalling ( ERK1,  ERS-1),  
No hypoglycemia in normoglycemic model. 
He36 2019 Mice  Liraglutide i.p.  u.l. pCCAO  OD for 7 days NP -  neurological deficit,  oxidative stress  
Zeng37 2020 Rat  Liraglutide i.p. P13k inhibitor u.l pMCAO  0 then OD NP -  infarct volume,  cerebral oedema,  apoptosis (  Bcl-2,  caspase-3,  TUNEL),  
inflammation ( TNF-, IL-18, IL-1, IL-6, COX-2)  
P13k inhibitor partially reversed NP effects. 
Abbreviations: 
Drugs: 
SA – single agonist 
DA – dual agonist  
Ex-4- exendin-4 
PEx-4– Exendin-4 loaded poly-microspheres 
Ex-9-39- GLP-1R antagonist 
pro-GLP-1– long acting GLP-1RA 
rhGLP-1– recombinant human GLP-1 
DMB– 6,7-dichloro-2-methyl-sulfonyl-3-N-tert-
butylaminoquinoxaline 
OXM– oxyntomodulin 
shRNA- small hairpin RNA (targets GLP-1R) 
BQ123- endothelin receptor antagonist 
P7C3- aminopropyl carbazole compound 
 
Administration: 
i.p. - intraperitoneal  
s.c. – subcutaneous 
p.o. – oral 
i.n. – intranasal  
t.v. – transvenous  
i.c.v. intracerebroventricular  
 
Frequency: 
OD/BD/TDS – once/twice/three times daily  
 
Models: 
DM – diabetes mellitus  
Non-DM – non diabetes mellitus (healthy) 
 
Induction methods: 
u.l. – unilateral 
b.l. – bilateral 
MCAO – middle cerebral artery occlusion 
CCAO – common carotid artery occlusion 
(t/p)MCAO – transient/permanent 
 
Oxidative stress parameters: 
SOD – superoxide dismutase 
MDA - malondialdehyde 
GSH – glutathione  
8-OHdG – 8-hydroxy-2-deoxyguanosine  
HHE – 4-hydroxyhexenal 
DHE – dihydroethidium  
ROS – reactive oxygen species  
 
Apoptosis markers: 
Bcl-2 – B cell lymphoma 2 
Bax – Bcl-2-like protein 4 
Caspase-3 
PARP – poly-ADP ribose polymerase 
TUNEL – terminal deoxynucleotidyl transferase dUTP nick end 
labelling 
 
 
 
Others: 
S100b – s100- calcium binding protein B 
NSE – neuron specific enolase  
MBP – myelin basic protein 
COX-2 – cyclo-oxygenase-2 
PE2 – Prostaglandin E2 
EAAT2 – Excitatory amino acid transporter-2 
MPO – myeloperoxidase 
HO-1 – heme oxygenase-1 
Nrf2 – nuclear factor erythroid-2 
NOS – nitric oxide synthase  
BBB – blood brain barrier  
MMP-9 – matrix metalloproteinase-9 
ICAM-1 – intracellular adhesion molecule-1 
NeuN – neuronal nuclear protein (neuronal marker) 
GFAP – Glial fibrillary acidic protein (glial marker) 
vWF – von Willebrand factor (endothelial marker) 
-tub3 – beta tubulin III 
GSK-3 – glycogen synthase kinase 3 
IL – interleukin  
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TABLE 2: GLP-1RA characteristics and stroke incidence in CVOTs   
 ELIXA75 LEADER76 SUSTAIN-677 EXSCEL78 HARMONY79 REWIND80 PIONEER-681 
GLP-1RA Lixisenatide Liraglutide Semaglutide Exenatide 
(extended release)  
Albiglutide Dulaglutide Semaglutide  
Participants 6 068 9 340 3 297 14 752 9 463 9 901 3 183 
Median follow-up (years) 2.1 3.8 2.1 3.2 1.6 5.4 1.3 
Characteristics       
Administration subcutaneous subcutaneous subcutaneous  subcutaneous subcutaneous subcutaneous Oral    
Dose 10 - 20g 1.8mg 0.5 - 1.0mg 2mg 30 - 50mg 1.5mg  14mg    
Frequency  once-daily once-daily once-weekly once-weekly* once-weekly once-weekly  Once-daily    
Non-fatal stroke incidence      
Treatment group – no. (%) 54 (1.8)  159 (3.4) 27 (1.6) 169 (2.3) 76 (1.6) 135 (2.7) 12 (0.8) 
Placebo – no. (%) 49 (1.6) 177 (3.8) 44 (2.7) 193 (2.6) 91 (1.9) 175 (3.5) 16 (1.0) 
Hazard ratio (95% CI) 1.10 (0.75-1.63)  
 
0.89 (0.72 - 1.11) 
P=0.30 
0.61 (0.38 - 0.99) 
P=0.04 
0.88 (0.72 - 1.08) 
 
0.84 (0.62 - 1.13) 
 
0.76 (0.61 - 0.94) 
P=0.017 
0.74 (0.35 - 1.57) 
 
*Exenatide standard release requires twice-daily administration  
 
  
 32 
 
TABLE 3: Retrospective database studies 
Author Years 
studied  
Participants 
included  
Groups  Participants on 
GLP-1RA 
GLP-1RA CVD  
risk (composite) 
- HR(95% CI) 
unless otherwise 
specified 
GLP-1RA 
Stroke Risk -
HR(95% CI) 
HR Compared to 
Best82 2005 - 
2009 
383 525  Exenatide, non-exenatide 21 754 0.80 (0.74 - 0.86) NR Non-exenatide 
Paul65 2005 - 
2009 
39 225  Exenatide, exenatide & 
insulin, insulin 
10 674 Exenatide 
0.50 (0.32 - 0.79) 
Exenatide & 
insulin 
0.44 (0.34 - 0.57) 
Exenatide  
0.50(0.28-
0.84) 
Exenatide & 
insulin 
0.38 (0.27 - 
0.54) 
Insulin 
Gejl83  1977 - 
2011 
10 073  Liraglutide, exenatide, 
insulin, biguianides, 
glitazones, DPP-4i, SFU 
1 749 Liraglutide 
OR 0.48 (0.38 - 
0.62) 
Exenatide 
OR 1.72 (1.20 - 
2.48)  
NR 
 
N/A 
Patorno84 2005 - 
2013 
219 810 GLP-1RA, DPP-4i, SFU, 
insulin 
29 542 i) 1.20 (0.76 - 1.89) 
ii) 1.05 (0.63 - 
1.74) 
iii) 1.01 (0.73 - 
1.41) 
NR i) DPP-4i  
ii) SFU 
iii) insulin 
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Ekström85 2005 - 
2012 
20 422 GLP-1RA, acarbose, 
insulin, DPP-4i, 
meglitinide, SU, TZD 
219 0.26 (0.10 - 0.67) NR Sulphonylurea  
Zimmerman66  2005 - 
2014 
105 862 GLP-1RA, non-GLP-1RA 8 362 0.82 (0.74 - 0.91) 0.82 (0.74 - 
0.91) 
Non-GLP-1RA 
Anyanwagu86 2006 - 
2014 
3 586  Insulin & GLP-1RA, 
insulin 
1 793 0.76 (0.41 -1.42) 0.93 (0.54 - 
1.61) 
Insulin 
O’Brien64 2011 - 
2015 
132 737 GLP-1RA, DPP-4i, SGLT-
2i, TZD, SFU, insulin 
11 351 0.78 (0.63 - 0.96) 0.65 (0.44 - 
0.97) 
DPP-4i 
Svanstrom67 2010 - 
2016 
46 804 Liraglutide, DPP-4i 23 402 0.90 (0.83 -0.98) 0.88 (0.77 - 
1.01) 
DPP-4i 
Raparelli69 2011 - 
2017 
167 254 GLP-1RA, DPP-4i, SGLT-
2i, SFU 
14 697 0.70 (0.62 - 0.78) 
Women only:  
0.57 (0.48 - 0.68) 
NR SFU 
 
Notes: Frison87 excluded as too small to calculate HR. NR- Not recorded, DPP-4i-dipeptidul peptidase-4 inhibitor, SFU-sulphonylurea, SGLT-2i-sodium-glucose cotransporter-2, TZD-thiazolidined
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